Aurinia Pharmaceuticals (AUPH)
(Delayed Data from NSDQ)
$11.37 USD
-0.06 (-0.52%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $11.36 -0.01 (-0.09%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth C Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AUPH 11.37 -0.06(-0.52%)
Will AUPH be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AUPH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AUPH
Aurinia (AUPH) Upgraded to Buy: Here's What You Should Know
Aurinia Pharmaceuticals (AUPH) Q2 Earnings Miss Estimates
AUPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Implied Volatility Surging for Aurinia Pharmaceuticals Stock Options
Aurinia (AUPH) Surges 7.5%: Is This an Indication of Further Gains?
Is the Options Market Predicting a Spike in Aurinia Pharmaceuticals (AUPH) Stock?
Other News for AUPH
Aurinia Pharma: The Easiest Money May Have Been Made (Rating Downgrade)
Aurinia Pharmaceuticals Reaches Analyst Target Price
Insider Sell: Greg Keenan Sells 20,000 Shares of Aurinia Pharmaceuticals Inc (AUPH)
Aurinia Pharmaceuticals: Strong Financial Performance and Promising Future Justify Buy Rating
AUPH Analyst Rating Update: RBC Capital Raises Price Target | AUPH Stock News